KEY OPINION LEADERS
Find out who has spoken at Galien Foundation
meetings and events
We are determined to ensure that Galien Foundation events are second-to-none in caliber. Our forums, meetings and digital events bring together the world’s thought leaders in one singular mission - to improve the human condition. Discover who has spoken at our events by searching below.
Who are you looking for?
| NAME | COMPANY | TITLE | EVENT | TOPIC | COUNTRY | |
|---|---|---|---|---|---|---|
| 2022 | Roderick Van Grieken | Nederlands Debat Instituut | Prix Galien Netherlands 2022 | Netherlands | ||
| 2022 | Nicky Hekster | Dr | Prix Galien Netherlands 2022 | Netherlands | ||
| 2022 | Koos Burggraaf | Prof | Prix Galien Netherlands 2022 | Netherlands | ||
| 2022 | Marc Bonten | Prof | Prix Galien Netherlands 2022 | Netherlands | ||
| 2022 | Lisette Van Gemert | Prof, Dr | Prix Galien Netherlands 2022 | Netherlands | ||
| 2022 | Mark Walport | Prof. Sir. Chair | Galien Forum UK 2022 | UK | ||
| 2022 | Mel Walker | BioPharma Futures | Dr. Moderator Biotech/Digital Health Adviser | Galien Forum UK 2022 (PANEL 2) | ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS | UK |
| 2022 | Andy Richards | Congenica Ltd, Owlstone Medical, Closed Loop Medicine and Ieso Digital Health | Dr. CBE I Chair | Galien Forum UK 2022 (PANEL 3) | DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? | UK |
| 2020 | Ted Johnson | Pfizer Oncology Pfizer Inc | Research Fellow, Medicinal Chemistry | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Ute Simon | AAA (a Novartis company) | Head Global Medical Affairs | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Santosh Prabhu | Abbott Structural Heart | Divisional Vice President, Product Development | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | Sailaja Bhaskar | Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P. | Executive Director, Clinical Operations Planning | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2020 | Pushkal Garg | Alnylam | Chief Medical Officer | Galien Week of innovation | Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? | USA |
| 2020 | Ponda Motsepe – Ditshego | Amgen Bone | Executive Medical Director | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Cen Xu | Amgen Neuroscience | Executive Director | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Roy Wiesner | aMoon | Managing Director | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2020 | Ramon Tiu | Astellas Pharma Inc. | Executive Medical Director, Astellas Pharma Global Development Global Medical Leader, Gilteritinib Program | Galien Week of innovation | Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? | USA |
| 2022 | Menelas (Mene) Pangalos | AstraZeneca | Prof. Sir. EVP & President BioPharmaceuticals R&D | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2020 | Marc Fellous | Bayer | Global Medical Affairs Head | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Jorge Ortiz | Bayer | Global Medical Affairs Head | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Jessica Federer | Bayer | Partner Boston Millenia Partners Former CDO | Galien Webinars | Digital Health Improving Research and Care | USA |
| 2020 | Michael Ringel | BCG | Managing Director and Senior Partner | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2022 | Myrto Lee | BCG | Dr. Moderator. Managing Director & Partner | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2020 | Stephanie Klocke | Becton, Dickinson and Company | Vice President of Research & Development | Galien Week of innovation | What is MedTech innovation doing for patients with specialized needs for treatment? | USA |
| 2020 | David Hayes | Biotronik | Chief Medical Officer | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | Shwen Gwee | Bristol Myers Squibb | VP and Head of Global Digital Strategy | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2020 | Kate Rosenbluth | Cala Health | Founding CEO & CSO | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Angela Radcliffe | CAPGEMINI INVENT | R&D Practice Lead,m Founding Member, CoS, IEEE Global Initiative to Standardize Fairness in the Trade of Data; Advisory Board Member to Startups in Life Science; Clinical Research Advocate | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2020 | Milind Kamkolkar | CELLARITY | Chief Digital & Data Officer | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2022 | Catherine Pollard | Centre for Improving Data Collaboration, NHSX | Director | Galien Forum UK 2022 (PANEL 3) | DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? | UK |
| 2020 | Barbara Fant | Clinical Research Consultants, Inc. | President | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Dr. Amir Kalali | CNS Summit | CO Chair, Decentralized Trials & Researched Alliance; Chief Currator and Chairman | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2020 | Javad Shahidi | Daiichi Sankyo | Vice President, Global Oncology R&D | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2020 | Uri Bettesh | Datos-Health | CEO | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2022 | Vishal Gulati | Deeptech / Healthtech VC | Dr. | Galien Forum UK 2022 (PANEL 3) | DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? | UK |
| 2020 | Flavio Manetlli | Dompé U.S. Inc. | Chief Medical officer | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2020 | Satasuk Joy Bhosai | Duke Clinical Research Institute | Chief of Digital Health and Strategy | Galien Webinars | Digital Health Improving Research and Care | USA |
| 2020 | Brian S. Conklin | Edwards Lifesciences | Senior Distinguished Engineer | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | Laksen Sirimanne | Edwards Lifesciences | Vice President, Research & Development | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | Eric M Pearlman | Eli Lilly and Company | Senior Medical Director-Migraine/Pain, Neuroscience Medical Affairs | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2020 | Douglas Schlichting | Eli Lilly and Company | Development Director Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19 | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2020 | Eric M Pearlman | Eli Lilly and Company | Senior Medical Director-Neuroscience, US Medical Affairs | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Dr. Eric Mayes | Endomag Ltd. | CEO | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Amy Abernethy | FDA | Principal Deputy Commissioner | Galien Webinars | Digital Health Improving Research and Care | USA |
| 2020 | Gil Bashe | Finn Partners | Managing Partner, Chair Global Health | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2020 | Gil Bashe | Finn Partners | Managing Partner, Chair Global Health | Galien Webinars | Digital Health Webinar – Presentation of the Nominees in the 2020 Prix Galien Digital Health Category | USA |
| 2020 | Gil Bashe | Finn Partners | Managing Partner, Chair Global Health | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2020 | Michael Rosenblatt | Flagship Pioneering, Cambridge, MA | Chief Medical Officer | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Jonathan Sorof | Global Blood Therapeutics | Senior Vice President, Head of Medical Affairs | Galien Week of innovation | Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? | USA |
| 2022 | Patrick Vallance | Government | Sir. Government Chief Scientific Adviser | Galien Forum UK 2022 (PANEL 2) | ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS | UK |
| 2022 | Christopher Corsico | GSK | Dr. Global Head of Development | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2021 | Michal Rosen-Zvi | IBM, Health Informatics | Director of Health Informatics | JEF 2021 | ARTIFICIAL INTELLIGENCE AND ETHICS | Israël |
| 2022 | Andy Blackwell | Ieso Digital Health | Dr. Chief Science and Strategy Officer | Galien Forum UK 2022 (PANEL 3) | DIGITAL HEALTH INNOVATION: A KEY DRIVER OF NEXT GENERATION HEALTHCARE – WHAT AND WHEN? | UK |
| 2020 | Ishu Rao | Impulse Dynamics | Medical Director | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | MaryAnne Rizk | IQVIA | Senior Vice President, R&D Digital Strategy | Galien Week of innovation | Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? | USA |
| 2020 | Dan Cua | Janssen Biotech, Inc. | Vice President IL-23 Pathway Area Leader for the Immunology Therapeutic Area | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Sabine Brookman-May | Janssen Research & Development, LLC | Executive Medical Director, Late Development, Solid Tumor | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Sam Spigelman | Janssen Research & Development, LLC | Senior Global Medical Affairs Leader | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Michael Michael | Karyopharm Therapeutics Inc | Chief Executive Officer Co-Founder | Galien Week of innovation | Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? | USA |
| 2020 | Steven J. Lester | Mayo Clinic-ASU MedTech Accelerator | Chief Medical Officer | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2022 | Alison Holland | Medable | Head of Decentralized Clinical Trials | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2020 | Mark Sullivan | Medicines Development for Global Health | Founder and Managing Director | Galien Week of innovation | Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? | USA |
| 2022 | Carole Longson | Medicines Discovery Catapult | Prof. Vice Chair | Galien Forum UK 2022 (PANEL 2) | ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS | UK |
| 2020 | Jessica Grossman | Medicines360 | CEO | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Robert Kowal | Medtronic | Chief Medical Officer, Vice President of Medical Affairs & Business Development | Galien Week of innovation | How much are new technologies and engineering efficiencies contributing to progress against the world’s biggest killer? | USA |
| 2020 | Beth-Ann Coller | Merck & Co., Inc | Executive Director, Global Clinical Development | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2020 | Amanda Paschke | Merck & Co., Inc. | Executive Director Global Clinical Development | Galien Week of innovation | Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? | USA |
| 2022 | Dame June Raine | MHRA | CEO | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2020 | Junaid Bajwa | Microsoft | Chief Medical Scientist | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2020 | Robert S. Langer | MIT | David H. Koch Institute Professor | Galien Week of innovation | What is MedTech innovation doing for patients with specialized needs for treatment? | USA |
| 2020 | Jane Metcalfe | Neo.Life. Wired Magazine | CEO, Co-Founder | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2022 | David Prior | NHS England | Lord. Chair | Galien Forum UK 2022 (PANEL 2) | ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS | UK |
| 2020 | Mimi Huizinga | Novartis | Vice President and HeaS Oncology Medical | Galien Week of innovation | Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? | USA |
| 2020 | Mimi Huizinga | Novartis | Vice President and Head, US Oncology Medical | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | David J. Lennon | Novartis Gene Therapies | President | Galien Week of innovation | Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? | USA |
| 2020 | David Platt | Novartis Pharmaceuticals Corporation | Vice President, Medical Unit Head Cardiovascular, Renal & Metabolism Medical Unit | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2020 | Mads Frederik Rasmussen | Novo Nordisk A/S | Corporate Project Vice President (CPVP) for GLP-1, CV and Outcomes | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Katherine Vandebelt | Oracle Health Science | Global Vice President, Clinical Innovation | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2022 | Martin Landray | Oxford University | Prof. Sir. Professor of Medicine and Epidemiology | Galien Forum UK 2022 (PANEL 1) | CLINICAL TRIALS & REGULATIONS: WHAT HAVE WE LEARNED FROM COVID? | UK |
| 2020 | Michelle Hoiseth | Parexel International | Chief Data Officer & Corporate VP Medical and Scientific Services | Galien Webinars | Digital Health Improving Research and Care | USA |
| 2020 | Yuri Maricich | Pear Therapeutics | Chief Medical Officer & Head of Development | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Sandi See Tai | Pfizer Global Product Development Pfizer Inc. | VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac | Galien Week of innovation | The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive. | USA |
| 2020 | Sri Radhakrishnan | Pulmonx Corporation | Chief Technical Officer | Galien Week of innovation | What is MedTech innovation doing for patients with specialized needs for treatment? | USA |
| 2020 | Marcella Ruddy | Regeneron | Vice President, Strategic Program Direction, Immunology and Inflammation | Galien Week of innovation | Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions? | USA |
| 2020 | Bernard Delaey | Sanofi | Regulatory Therapeutic Area Lead | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2020 | Tanya Lewis | Scientific American | Associate Editor for Health and Medicine | Galien Week of innovation | Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments? | USA |
| 2020 | Dennis Hruby | SIGA Technologies, Inc. | Chief Scientific Officer | Galien Week of innovation | Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? | USA |
| 2020 | Theodore F. Search | Skipta | Chief Executive Officer | Galien Week of innovation | Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia? | USA |
| 2020 | Theodore F. Search | Skipta | Chief Executive Officer | Galien Week of innovation | What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation? | USA |
| 2020 | Bjarne Bergheim | Sonendo, Inc | President and Chief Executive Officer | Galien Week of innovation | What is MedTech innovation doing for patients with specialized needs for treatment? | USA |
| 2020 | Eugene Kandel | Start Up Nation Central | CEO | Galien Webinars | Digital Health in the Aftermath of COVID-19 | USA |
| 2020 | Dan Sexton | Takeda Pharmaceutical Company Limited | Strategy Lead | Galien Week of innovation | Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions? | USA |
| 2020 | Daniel Everitt | TB Alliance | Vice President and Chief Medical Officer | Galien Week of innovation | Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall? | USA |
| 2020 | Mark Milton-Edwards | Teva Pharmaceutical Industries | Head of Product & Health Solutions – Digital Health | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Alon Iron | THERANICA | President & CEO, Co-founder | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2020 | Susannah Fox | U.S. Department of Health and Human Services | Independent Consultant and Health Care Innovation Leader & Former Chief Technology Officer | Galien Week of innovation | How far are we from achieving the health system world of the connected patient? | USA |
| 2020 | Hilary Malone | Valo Health | Chief Operating Officer | Galien Webinars | Digital Health Improving Research and Care | USA |
| 2020 | Tal Wenderow | VOCALIS HEALTH | CEO | Galien Webinars | The Digital Health Enterprise: Start-Up Trends and the Culture of Big Pharma | USA |
| 2022 | Samantha Roberts | NICE | Dr. CEO | Galien Forum UK 2022 (PANEL 2) | ACCESS TO INNOVATION: OPTIMIZING HEALTH FOR PATIENT POPULATIONS | UK |
| 2021 | Emmanuel Fombu | Medical Futurist | JEF 2021 | ARTIFICIAL INTELLIGENCE AND ETHICS | Israël | |
| 2021 | Ayman Salem | Neurosurgeon | JEF 2021 | ARTIFICIAL INTELLIGENCE AND ETHICS | Israël |
TOP SCIENTISTS & KOL